Esperion Therapeutics, Inc. (ESPR)

NASDAQ: ESPR · Real-Time Price · USD

3.480

-0.040 (-1.14%)

Feb 20, 2026, 4:00 PM EST - Market closed

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Researching, Developing and Commercializing Therapies	332.31M	116.33M	75.48M	78.45M	227.55M
Researching, Developing and Commercializing Therapies Growth	185.66%	54.14%	-3.79%	-65.52%	53.37%
Total	332.31M	116.33M	75.48M	78.45M	227.55M
Total Growth	185.66%	54.14%	-3.79%	-65.52%	53.37%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	332.31M	116.33M	75.48M	78.45M	227.55M
United States Growth	185.66%	54.14%	-3.79%	-65.52%	53.37%
Total	332.31M	116.33M	75.48M	78.45M	227.55M
Total Growth	185.66%	54.14%	-3.79%	-65.52%	53.37%

Source: S&P Global Market Intelligence.